Ivermectin Topical Preparation Veterinary Grade API is a semisynthetic macrocyclic lactone active substance obtained by selective reduction of abamectin B1a/B1b from Streptomyces avermitilis fermentation. The technical reference designation IVM-VET-API denotes the veterinary-grade active substance, not a finished topical product; it is supplied to manufacturers of tablets, injections, capsules, powders, granules, premixes, and topical or oral solutions. The API is defined as a mixture containing ≥80.0% 22,23-dihydroavermectin B1a and ≤20.0% 22,23-dihydroavermectin B1b, with an assay on the dried basis of 95.0–102.0% w/w by liquid chromatography. The B1a component has CAS RN 70288-86-7, molecular formula C₄₈H₇₄O₁₄, and molecular weight 875.10 g/mol; the B1b component has molecular formula C₄₇H₇₂O₁₄ and molecular weight 861.07 g/mol. The powder is white to off-white and crystalline. Its intrinsic aqueous solubility is below 10 mg/L at 25 °C, and this low solubility is the principal determinant of formulation design across all dosage forms. Pharmacopoeial identity is confirmed by infrared absorption spectrophotometry per Ph.Eur. 2.2.24 or USP <197>, and assay is performed by liquid chromatography per Ph.Eur. 2.2.29 or USP <621>.

What Separates Veterinary-Grade Ivermectin API from Abamectin, Doramectin, Eprinomectin, and Human-Grade Material?

The structural distinction is the saturated C-22–C-23 bond. Abamectin retains an unsaturated C-22–C-23 avermectin B1a/B1b pair; ivermectin is the semisynthetic 22,23-dihydro derivative. This single reduction changes environmental degradation kinetics and confers the activity profile expected in veterinary endo- and ectoparasiticidal products. Doramectin has a cyclohexyl group at C-25, eprinomectin carries a 4″-epi-acetylamino substituent, and moxidectin belongs to the milbemycin class; these are not interchangeable with ivermectin in a formulation without bioequivalence and residue-depletion data. Veterinary-grade ivermectin also differs from agricultural-grade abamectin because the veterinary API is released under EU GMP Part II / ICH Q7, with a defined impurity profile, residual solvent profile, endotoxin control, and a BSE/TSE statement. Human-grade material may not carry the same veterinary-specific documentation or may not have been evaluated for maximum residue limits applicable to food-producing species.

The release documentation for production-scale lots of IVM-VET-API combines compendial purity tests with processability controls. The core specification profile is shown below; injectable and topical grades are tightened for moisture, bioburden, and endotoxin.

For parenteral and ophthalmic-grade topical material, bacterial endotoxins are tested by the LAL method per Ph.Eur. 2.6.14 or USP <85>, with an acceptance limit calculated from the maximum intended dose and species. The manufacturer’s active substance master file should contain the residual solvent calculation under VICH GL18, because the semisynthetic reduction and recrystallization steps can introduce methanol, ethanol, or dichloromethane. A default limit of 3000 ppm for methanol and 600 ppm for dichloromethane is not applicable unless the daily dose supports the exposure; the calculation must use the permitted daily exposure and the maximum daily dose of the finished veterinary product.

When Sterile Filtration and Endotoxin Control Define Injectable Formulation Limits

Injectable solutions containing ivermectin are usually prepared as non-aqueous or mixed-solvent systems because the intrinsic aqueous solubility is below 10 mg/L. Typical vehicles include propylene glycol, glycerol formal, and lower alcohols, with a final ivermectin concentration of 1.0% w/v in many veterinary parenteral products. The manufacturing process is challenged at the sterile filtration step: the viscosity of glycerol formal–propylene glycol blends can exceed 30 mPa·s at 20 °C, reducing sterilizing-grade membrane throughput. A 0.45 µm prefilter is placed before the 0.22 µm final membrane to protect surface area. The filter housing, tubing, and receiving vessel must be preflushed with filtered solvent to reduce particulate matter; final product is tested according to Ph.Eur. 2.9.19 or USP <788> for subvisible particles. Bacterial endotoxin control is performed by the LAL method per Ph.Eur. 2.6.14 or USP <85>, with the acceptance limit tied to the maximum single dose and the animal species. Sterility testing is conducted per Ph.Eur. 2.6.1 or USP <71>. Production-scale experience shows that moisture ingress above 30% RH during compounding can generate visible opalescence and eventual precipitation; therefore isolator or controlled room conditions below 30% RH are used where validated. The solvent blend must be pre-dried or specified with low water content, and the API is dried to ≤0.5% w/w water before charging.

Tablet and capsule processing is constrained by the cohesive nature of the crystalline API and its low aqueous solubility. Direct compression is generally feasible only for low-dose veterinary tablets at labelled strengths below 5 mg; higher strengths require wet granulation or roller compaction. In fluid-bed granulators, a validated inlet air temperature of 45–55 °C and a bed dew point below 10 °C reduce the risk of granule over-wetting. The spray rate is adjusted to the nozzle geometry and the batch load; values near 8–12 g/min per kg of dry substrate are used as a starting range and are not universal acceptance limits. The final blend is tested for powder flow and compressibility. A Carr compressibility index below 25% and a Hausner ratio below 1.25 are typical release targets for capsule filling and tablet compression. Dissolution testing is product-specific; no single compendial acceptance criterion applies to all veterinary ivermectin tablets. The finished tablet method must be validated according to VICH GL2 and is typically run in USP apparatus 2 with a surfactant-containing medium, but published data for this specific API are limited.

Microbiological quality of the non-sterile API is controlled according to Ph.Eur. 2.6.12 and USP <61>. The acceptance limit for total aerobic microbial count is generally 10² CFU/g or 10³ CFU/g depending on the intended route; for oral premix and oral solution intermediates, a tighter limit may be imposed because the API is not subjected to a sterilizing step. The combined yeasts and moulds count is typically 10¹ CFU/g. For injectable and ophthalmic topical routes, the same API lot is tested for bacterial endotoxins and may be subjected to a pre-sterilization bioburden limit such as ≤10 CFU/100 mL of the compounded solution before filtration. The exact bioburden alert and action limits are established in the contamination control strategy of the manufacturing site, not by the API monograph alone.

Premix Carrier Selection and Particulate Uniformity for Feed Delivery

For medicated feed premixes, the API is dispersed onto lactose monohydrate, corncob grit, or mineral carriers. The critical process risk is segregation during pneumatic conveying, not chemical instability. The median particle size D50 of the API powder is commonly maintained between 10 µm and 50 µm for adherence to larger carrier particles; however, the optimum is product-specific and must be established by laser diffraction per ISO 13320:2020. Blend uniformity is tested according to VICH GL2 and the pharmacopoeial content-uniformity chapter; active substance content in the finished premix is typically controlled within ±10% of label claim. Bin-blender fill levels below 30% or above 70% of working capacity can create dead zones or reduce diffusive mixing. In feed mills, premix inclusion rates may be below 0.5 kg/tonne of finished feed, so the carrier particle size distribution and bulk density must be matched to the feed base to minimize sifting. Published data for this specific API–carrier configuration are limited; validation is lot-specific.

Topical pour-on and solution dosage forms exploit the solubility of ivermectin in organic solvents such as propylene glycol, glycerol formal, and isopropyl alcohol. When a true solution is not feasible, micronized API with a D90 not more than 30 µm is used to reduce sedimentation and skin grittiness. Air-jet milling is performed with dried compressed air or nitrogen because the micronized powder can accumulate static charge and adhere to mill internals; the milled batch is sampled for particle size and bulk/tapped density. Oral solutions are formulated with non-aqueous vehicles or water-miscible co-solvents; any aqueous dilution must not exceed the co-solvent capacity of the system or the API will precipitate. The API should be stored in a tight container protected from light at or below 25 °C. In use, exposure to strong oxidizing agents and prolonged contact with aqueous acidic or alkaline solutions should be evaluated for degradation; published kinetic data for this specific veterinary API are limited.

For semisolid topical preparations, the API is incorporated into an ointment or emulsion base by high-shear dispersion. The dispersed phase must be de-aerated before packaging because the crystalline powder can stabilize fine air bubbles, leading to apparent density variation. The particle size specification is confirmed by microscopy or laser diffraction. In an oil-in-water cream, ivermectin resides primarily in the oil phase; if the formulation is diluted with water the drug may recrystallize at the interface. A penetration enhancer is not required for the API to exert local or systemic effect, but the finished product must meet viscosity and dose uniformity limits under Ph.Eur. 2.2.10 or USP <915> where applicable. The active substance is light-sensitive; the finished topical container should be selected to limit photodegradation, and stability studies should be conducted under VICH GL3 conditions in the proposed packaging.